VTX3232, a CNS-penetrant NLRP3 Inhibitor, is conducting a Phase 2a clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with Early-Stage Parkinson’s Disease [37]. The gene discussed is NLRP3; the disease is Parkinson disease.